References
- 1. Kim K, Hernlund E, Hernadi Z, Révész J, Pete I, Szánthó M, et al. Treatment patterns, health care utilization, and costs of ovarian cancer in Central and Eastern Europe using a Delphi panel based on a retrospective chart review. Int J Gynecol Cancer 2013; 23(5):823-32.
- 2. André N, Banavali, S, Snihur Y, Pasquier E. Has the time come for metronomics in low-income and middle-income countries? The Lancet Oncology 2013;14(6), e239-48.
- 3. Lazić Z, Gajović O, Tanasković I, Milovanović D, Atanasijević D, Jakovljević, M. GOLD Stage Impact on COPD Direct Medical Costs in Elderly. Journal of Health Behavior and Public Health 2012; 2(3):1-7.
- 4. Cupurdija, V., Lazic, Z., Petrovic, M., Mojsilovic, S., Cekerevac, I., Rancic, N., & Jakovljevic, M. (2015). Community-acquired pneumonia: economics of inpatient medical care vis-à-vis clinical severity*, *. J Bras Pneumol, 41(1), 48-57.
- 5. Jovanović M, Jakovljević M. Inpatient detoxification procedure and facilities: financing considerations from an Eastern European perspective. Alcohol and Alcoholism 2011; 46(3):364-5.
- 6. Biorac N, Jakovljević M, Stefanović D, Perović S, Janković S. Assessment of diabetes mellitus type 2 treatment costs in the Republic of Serbia. Vojnosanit Pregl 2009; 66(4):271-6.
- 7. Jakovljević M, Mijailović Z, Jovičić BP, Čanović P, Gajović O, Jovanović et al.. Assessment of viral genotype impact to the cost-effectiveness and overall costs of care for PEG-interferon-2α + ribavirine treated chronic hepatitis C patients. Hepat Mon 2013;19:13(6):e6750.
- 8. Jakovljević M, Varjačić M, Janković SM. Cost-effectiveness of ritodrine and fenoterol for treatment of preterm labor in a low-middle-income country: a case study. Value Health 2008;11(2):149-53.
- 9. Ranković A, Rančić N, Jovanovic M, Ivanovic M, Gajovic O, Lazic Z. et al. Impact of imaging diagnostics on the budget – Are we spending too much? Vojnosanit Pregl 2013; 70(7): 709–11.
- 10. Jakovljević M, Ranković A, Rancic N, Jovanović M, Ivanović M, Gajović O, et al. Radiology Services Costs and Utilization Patterns estimates in Southeastern Europe - A Retrospective Analysis from Serbia. Value in Health Regional Issues CEEWAA 2013;10.1016/j. vhri.2013.07.002.
- 11. Jakovljevic, M., Gutzwiller, F., Schwenkglenks, M., Milovanovic, O., Rancic, N., Varjacic, M., ... & Matter-Walstra, K. (2014). Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. JBUON, 19(3), 1111-1120.
- 12. Jakovljević MB. Oncology monoclonal antibodies expenditure trends and reimbursement projections in the emerging Balkan market. Farmeconomia. Health economics and therapeutic pathways 2014;15(1):27-32.
- 13. Jakovljević M., Jovanović M, Lazić Z, Jakovljević V, Đukić A, Veličković R et al. Current efforts and proposals to reduce healthcare costs in Serbia. Serbian Journal of Experimental and Clinical Research 2011;12(4):161-3.
- 14. Kaló Z, Landa K, Doležal T, Vokó Z. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. Eur J Cancer Care 2012; 21(4): 442-9.
- 15. Jakovljević MB. Resource allocation strategies in Southeastern European health policy. Eur J Health Economics: HEPAC: health economics in prevention and care. 2013; 14(2):153-9.
- 16. Malik NN. Controlling the cost of innovative cancer therapeutics. Nature reviews. Clinical Oncology 2009;6(9):550-2.
- 17. Radovanović A, Dagović A, Jakovljević M. Economics of cancer related medical care: estimates worldwide and available domestic evidence. Archive of Oncology, 2011:19(3-4):59-63.
- 18. Nanda A, Nossikov A, Prokhorskas R, Shabanah MH Health in the central and eastern countries of the WHO European Region: an overview. World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales 1993; 46(3):158-65.
- 19. Institute of public health of Serbia “Dr Milan Jovanovic Batut”. Department for Prevention and Control of Noncommunicable Diseases. Cancer incidence and mortality in central Serbia, Report No. XII (2012). http://www.batut.org.rs/download/publikacije/Registar%20za%20rak%20u%20Centralnoj%20Srbiji%202010.pdf (Accessed 30 August 2013)
- 20. Institute of Public Health of Serbia, Belgrade “Dr Milan Jovanovic Batut” Health Statistical Yearbook of Republic of Serbia 2011. http://www.batut.org.rs/download/publikacije/pub2011.pdf(2012). (Accessed 30 August 2013)
- 21. Chiesa F, Tradati N, Calabrese L, Gibelli B, Giugliano G, Paganelli G, et al. Thyroid disease in northern Italian children born around the time of the Chernobyl nuclear accident. Ann Oncol 2004; 15(12):1842-6.
- 22. Papathanasiou K, Gianoulis C, Tolikas A, Dovas D, Koutsos J, Fragkedakis N, et al. Effect of depleted uranium weapons used in the Balkan war on the incidence of cervical intraepithelial neoplasia (CIN) and invasive cancer of the cervix in Greece. Clinical and Experimental Obstetrics & Gynecology 2005;32(1):58-60.
- 23. Obradović M, Mrhar A, Kos M. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia. European journal of public health 2010; 20(4): 415-21.
- 24. Kovacevic A, Dragojevic-Simic V, Rancic N, Jurisevic M, Gutzwiller F, Matter-Walstra K, Jakovljevic M, End-of-life costs of medical care for advanced stage cancer patients, Vojnosanit Pregl 2015; 72(4): 1–10.
- 25. Bechev D. The Periphery of the periphery: the Western Balkans and the Euro Crisis. European Council on Foreign Relations, 2012.
- 26. Panagiotou, Ritsa A. Effects of the global economic crisis on South-east Europe. Journal of Balkan and Near Eastern Studies 2010;12:187-94.
- 27. Stuckler, D., Basu, S., Suhrcke, M., Coutts, A., & McKee, M. (2009). The public health effect of economic crises and alternative policy responses in Europe: an empirical analysis. The Lancet, 374(9686), 315-323. Mazza R, Lina M, De Marco C, Pozzi P, Boffi R. Prevention and cancer care in Italy at the time of the world economic crisis. Epidemiol Prev 2013;37(4-5):193
- 28. Jakovljevic M, Vukovic M, Antunović, M, Veličković R, Siladji Djendji A, Janković, et al. (Do policy measures impact cost consciousness of healthcare professionals? Value in Health 2013; 16(7): A542.
- 29. Kentikelenis, A., Karanikolos, M., Papanicolas, I., Basu, S., McKee, M., & Stuckler, D. (2011). Health effects of financial crisis: omens of a Greek tragedy. The Lancet, 378(9801), 1457-1458.
- 30. Jakovljevic MB, Targeted immunotherapies overtaking emerging oncology market value based growth, forthcoming JBUON 2015; 20(1): 348-353.
- 31. Motheral, B., Brooks, J., Clark, M.A., Crown, W.H., Davey, et al. A checklist for retrospective database studies-report of the ISPOR Task Force on Retrospective Databases. Value in health. Journal of the International Society for Pharmacoeconomics and Outcomes Research 2003; 6(2):90-7.
- 32. Puder KL, Wood LL, Sherrill A. Health economics with retrospective data: selection bias issues. The Journal of international medical research 1997; 25(1): 45-51.
- 33. Medicines and Medicals Devices Agency of Serbia. Preparation of Professional Publications of the Agency. Belgrade, 2014. Available at: http://www.alims.gov.rs/eng/about-agency/publication/ (last accessed February 2014).
- 34. Wild F. Increases in pharmaceutical expenditures of PHI by monoclonal antibodies. Versicherungsmedizin 2013; 65(2), 91-3.
- 35. Jakovljević MB, Nakazono S, Ogura S. Contemporary generic market in Japan - key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):181-94.
- 36. Witteveen PO, van Groenestijn MA, Blijham GH, Schrijvers AJ. Use of resources and costs of palliative care with parenteral fluids and analgesics in the home setting for patients with end-stage cancer. Ann Oncol 1999; 10(2):161-5.
- 37. Kovačević A, Tarabar D, Jakovljević M, Dragojević-Simić V. Colorectal carcinoma chemotherapy: current status and future directions, Pharmaca Serbica 2011;3(3-4):20-5.
- 38. Viale PH, Grande C, Moore S. Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. Clinical journal of oncology nursing, 2012;16(4):e133-141.
- 39. The Republic Fund of Health Insurance. Republic of Serbia. http://www.eng.rfzo.rs Accessed 30 August 2013.
- 40. Kolodziej M, Hoverman JR. Value-based reimbursement in oncology. Am J Manag Care 2012;18(3 Spec No.):SP124-6.
- 41. Ward JC. Oncology reimbursement in the era of personalized medicine and big data. J Oncol Pract. 2014;10(2):83-6.
- 42. Tanneberger S, Pannuti F, Mirri R, Panetta A, Mariano P, Giordani S, et al. Home hospital for advanced stage cancer patients: costs and benefits. Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 1997; 91(2):117-23.
- 43. Konstantinović D, Lazarević V, Milovanović V, Lapcević M, Konstantinović V, Vuković M. Financial sustainability of home care in the health system of the Republic of Serbia. Srp Arh Celok Lek 2013;141(3-4):214-8.
- 44. Gajić-Stevanović M, Teodorović N, Dimitrijević S, Jovanović D. Assessment of financial flow in the health system of Serbia in a period 2003-2006. Vojnosanit Pregl. 2010;67(5):397-402.
- 45. World Health Organization. Guide to producing national health accounts: with special applications for low-income and middle-income countries. 2003.
- 46. Berman P. A. National health accounts in developing countries: appropriate methods and recent applications. Health Economics 1997; 6(1), 11-30.
- 47. Yamada, T., Chen, C. C., Yamada, T., Fahs, M., & Fukawa, T. (2006). Behavioral analysis of the choice of community-based formal home care, informal home care and nursing home care in Japan. The Geneva Papers on Risk and Insurance-Issues and Practice, 31(4), 600-632.
- 48. Barfar E, Rashidian A, Hosseini H, Nosratnejad S, Barooti E, Zendehdel K.Cost-effectiveness of mammography screening for breast cancer in a low socioeconomic group of Iranian women. Arch Iran Med. 2014;17(4):241-5.
- 49. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin DJ, Ichikawa L. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995; 87(6): 417-26.
- 50. Zavras A, Andreopoulos N, Katsikeris N, Zavras D, Cartsos V, Vamvakidis A. Oral cancer treatment costs in Greece and the effect of advanced disease. BMC Public Health 2002;2:12
- 51. Macioch T, Hermanowski T. The indirect costs of cancer-related absenteeism in the workplace in Poland. Journal of occupational and environmental medicine 2011; 53(12):1472-7.
- 52. Macklis R, Lasher J. Palliative radiotherapy for skeletal metastases: cost-substitution analyses and economic impact. J Oncol Manag 1999;8(2):17-22.
- 53. Larkin PJ, Dierckx de Casterlé B, Schotsmans P. Transition towards end of life in palliative care: an exploration of its meaning for advanced cancer patients in Europe. J Palliat Care 2007;23(2):69-79.
- 54. Jakovljevic M, Zugic A, Rankovic A, Dagovic A. Radiation Therapy Remains The Key Cost Driver Of Oncology Inpatient Treatment. J Med Econ. 2014 Sep 30:1-15. doi:10.3111/13696998.2014.971162.
- 55. Barton MB, Gebski V, Manderson C, Langlands AO. Radiation therapy: are we getting value for money? Clinical oncology (Royal College of Radiologists (Great Britain1995; 7(5): 287-92.
- 56. Van Loon J, Grutters J, Macbeth F. Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it? The Lancet Oncology 2012; 13(4): e169-77.
- 57. Rescigno P, Imbevaro S, Jirillo A. The economic crisis and cancer chemotherapy: the role of the oncologist. Tumori 2012; 98(4): 532-3.
- 58. Zweifel P. The Grossman model after 40 years. The European journal of health economics : HEPAC : health economics in prevention and care, 2012; 13(6); 677-82.
- 59. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D. ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16(2):231-50.
- 60. Uyl-de Groot CA. (2006) Economic evaluation of cancer therapies: More and better studies will lead to better choices in cancer care. Eur J Cancer; 42(17), 2862-6.